全文获取类型
收费全文 | 1409篇 |
免费 | 85篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 119篇 |
妇产科学 | 19篇 |
基础医学 | 130篇 |
口腔科学 | 52篇 |
临床医学 | 181篇 |
内科学 | 369篇 |
皮肤病学 | 23篇 |
神经病学 | 29篇 |
特种医学 | 238篇 |
外科学 | 96篇 |
综合类 | 35篇 |
预防医学 | 65篇 |
眼科学 | 30篇 |
药学 | 39篇 |
1篇 | |
肿瘤学 | 75篇 |
出版年
2021年 | 10篇 |
2020年 | 10篇 |
2019年 | 9篇 |
2018年 | 17篇 |
2017年 | 17篇 |
2016年 | 14篇 |
2015年 | 28篇 |
2014年 | 41篇 |
2013年 | 37篇 |
2012年 | 36篇 |
2011年 | 50篇 |
2010年 | 58篇 |
2009年 | 58篇 |
2008年 | 55篇 |
2007年 | 27篇 |
2006年 | 32篇 |
2005年 | 31篇 |
2004年 | 22篇 |
2003年 | 39篇 |
2002年 | 38篇 |
2001年 | 29篇 |
2000年 | 24篇 |
1999年 | 33篇 |
1998年 | 88篇 |
1997年 | 87篇 |
1996年 | 93篇 |
1995年 | 62篇 |
1994年 | 53篇 |
1993年 | 46篇 |
1992年 | 21篇 |
1991年 | 24篇 |
1990年 | 12篇 |
1989年 | 41篇 |
1988年 | 30篇 |
1987年 | 38篇 |
1986年 | 19篇 |
1985年 | 30篇 |
1984年 | 21篇 |
1983年 | 20篇 |
1982年 | 17篇 |
1981年 | 17篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 8篇 |
1976年 | 11篇 |
1975年 | 10篇 |
1969年 | 4篇 |
1968年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有1506条查询结果,搜索用时 15 毫秒
31.
Alloimmunization to platelets in heavily transfused patients with sickle cell disease 总被引:2,自引:0,他引:2
Bone marrow transplantation (BMT) is now an option for some patients with sickle cell disease (SCD). Many SCD patients are multiply transfused with red blood cells (RBCs), and may be immunized to alloantigens other than erythrocyte antigens. Because platelet refractoriness is a significant complication during BMT, we wished to determine the prevalence of alloimmunization to platelets in transfused SCD patients. Sera collected from 47 transfused and 14 untransfused SCD patients were screened for HLA and platelet-specific antibodies. Transfusion and RBC antibody histories were reviewed. A subset of the patients were rescreened 1 year later. Eighty-five percent of patients with at least 50 RBC transfusions (22 of 26), 48% of patients with less than 50 transfusions (10 of 21), and none of 14 untransfused patients demonstrated platelet alloimmunization (P < .05). Platelet alloimmunization was more prevalent than RBC alloimmunization (20% to 30%). Half of the platelet reactivity was chloroquine-elutable. Eighteen of 22 patients (82%) on chronic RBC transfusion remained platelet-alloimmunized 11 to 22 months after initial testing. In summary, 85% of heavily transfused SCD patients are alloimmunized to HLA and/or platelet-specific antigens. These patients may be refractory to platelet transfusion, a condition that would increase their risk during BMT. Leukodepletion in the transfusion support of SCD patients should be considered to prevent platelet alloimmunization. 相似文献
32.
Papadaki HA Tsagournisakis M Mastorodemos V Pontikoglou C Damianaki A Pyrovolaki K Stamatopoulos K Fassas A Plaitakis A Eliopoulos GD 《Bone marrow transplantation》2005,36(12):1053-1063
Bone marrow (BM) stem cell reserves and function and stromal cell hematopoiesis supporting capacity were evaluated in 15 patients with multiple sclerosis (MS) and 61 normal controls using flow cytometry, clonogenic assays, long-term BM cultures (LTBMCs) and enzyme-linked immunosorbent assays. MS patients displayed normal CD34+ cell numbers but a low frequency of colony-forming cells (CFCs) in both BM mononuclear and purified CD34+ cell fractions, compared to controls. Patients had increased proportions of activated BM CD3+/HLA-DR+ and CD3+/CD38+ T cells that correlated inversely with CFC numbers. Patient BM CD3+ T cells inhibited colony formation by normal CD34+ cells and patient CFC numbers increased significantly following immunomagnetic removal of T cells from BMMCs, suggesting that activated T cells may be involved in the defective clonogenic potential of hematopoietic progenitors. Patient BM stromal cells displayed normal hematopoiesis supporting capacity indicated by the CFC number in the nonadherent cell fraction of LTBMCs recharged with normal CD34+ cells. Culture supernatants displayed normal stromal derived factor-1 and stem cell factor/kit ligand but increased flt-3 ligand levels. These findings provide support for the use of autologous stem cell transplantation in MS patients. The low clonogenic potential of BM hematopoietic progenitors probably reflects the presence of activated T cells rather than an intrinsic defect. 相似文献
33.
We have previously reported that lithium chloride (LiCl) stimulates the production of granulocyte-macrophage colony-forming cells (GM-CFC), pluripotent stem cells (CFU-S), and differentiated granulocytes, macrophages and megakaryocytes in murine Dexter marrow cultures and that this effect appears to be mediated indirectly by a radioresistant adherent marrow cell. In this study we have established that exposure of murine Dexter cultures to LiCl (4 mEq/L) causes an increase of colony-forming cell megakaryocytes (CFU-meg) over 1 to 6 weeks of culture in both supernatant (188% to 611%) and stromal phases (123% to 246%). Moreover, we have shown that lithium treatment of either irradiated (1,100 rad) or unirradiated stromal cells increased production of activities stimulating formation of megakaryocyte, granulocyte, macrophage, and mixed lineage colonies and proliferation of the factor-dependent cell line, FDC-P1. This FDC-P1 stimulatory activity was completely blocked by an antibody to purified recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF). The baseline or lithium-induced--stromal-derived bone marrow colony stimulating activity was partially blocked by the antibody to rGM-CSF and by an antibody to purified colony stimulating factor I (CSF-1); the two antibodies combined resulted in greater than 90% inhibition of the lithium-induced marrow stimulatory activity. In addition, radioimmunoassay (RIA) showed that although CSF-1 was detectable in supernatants of these cultures, exposure to lithium did not increase CSF-1 levels. These data indicate that Dexter stromal cells produce CSF- 1 and GM-CSF and that lithium appears to exert its stimulatory effects on in vitro myelopoiesis by inducing production of GM-CSF. 相似文献
34.
Immunologic status of hemophilia patients treated with cryoprecipitate or lyophilized concentrate 总被引:1,自引:0,他引:1
We evaluated 37 patients with moderate or severe hemophilia A and six patients with severe factor IX deficiency for clinical or laboratory evidence of immune abnormalities. Patients were assigned to one of four groups according to the type of clotting factor replacement. Twenty patients had received only cryoprecipitate during the two years preceding the evaluation (group I); 11 additional patients were treated predominantly with cryoprecipitate but had also received up to nine bottles of factor VIII concentrate (group II); six patients received factor VIII concentrate (group III); six patients received factor IX concentrate (group IV). There was no clinical or laboratory evidence of immunodeficiency among the 43 patients. The mean absolute number of Th cells was normal in all patient groups, but the mean absolute number of Ts cells was increased compared with controls, both in patients treated with cryoprecipitate and in patients treated with factor VIII or factor IX concentrate. There was no correlation between the Th/Ts ratio and patient age, alanine aminotransferase level, hepatitis serology, in vitro lymphocyte function, or amount of clotting factor administered. Our observations demonstrate that the volunteer or commercial origin of clotting factor replacement cannot fully explain the alterations in lymphocyte subset distribution previously described in patients with hemophilia A. 相似文献
35.
36.
Papadaki HA Eliopoulos DG Ponticoglou C Eliopoulos GD 《International journal of hematology》2001,73(3):339-345
This study describes the frequency of monoclonal gammopathy of undetermined significance (MGUS) and the changes in some inflammation-related serum proteins in 157 patients with nonimmune chronic idiopathic neutropenia syndrome (NI-CINS). Of these patients, 42 had pronounced neutropenia with neutrophil counts < 1500/microL, and 115 had mild neutropenia with neutrophil counts ranging from 1500 to 2499/microL. Sixty-six volunteers served as healthy control subjects and 157 age- and sex-matched patients hospitalized for nonmalignant diseases served as patient control subjects. We found that 28.6% of patients with pronounced neutropenia and 14.8% of patients with mild neutropenia had increased serum gamma globulins (above the 95% confidence limit of values of the control subjects). In the group of patients with pronounced neutropenia, 30.9% had increased immunoglobulin (Ig)G values and 23.8% had increased IgA values. In the group of patients with mild neutropenia, 17.4% had increased IgG values and 21.7% had increased IgA values. IgG and IgA values strongly correlated with the neutrophil count. No changes in serum IgM were found. Three of 42 patients with pronounced neutropenia (7.14%) and 3 of 115 patients with mild neutropenia (2.61%) had serum immunofixation tests which showed a small monoclonal spike--4 were IgG-kappa type, 1 was IgG-lambda type, and 1 was IgA-kappa type. None of the healthy or patient control subjects had any evidence of MGUS. No significant changes in the amount of monoclonal spikes were documented during an 18- to 143-month follow-up (median, 58 months). Except for significantly increased alpha1-antitrypsin levels, there were no significant differences in the levels of acute-phase proteins studied between the study patients and the control subjects. These findings are consistent with our previous report suggesting the possible existence of an unrecognized low-grade chronic inflammation in patients with NI-CINS, which may be involved in the pathogenesis of neutropenia in the affected subjects. 相似文献
37.
A statistical analysis of murine stem cell suicide techniques 总被引:1,自引:0,他引:1
The clinical application of soft agar cloning techniques for granulocyte-macrophage stem cells (CFU-C) has resulted in a number of contradictory reports that may in part be due to an inadequate data base. Growth of murine CFU-C is more reproducible and less variable than that of human CFU-C. We utilized in vivo hydroxyurea suicide of murine marrow CFU-C to address the question of how many experiments are needed to detect a specific difference with a p of less than 0.05. In 66 experiments the mean marrow CFU-C hydroxyurea kill was 23.3%; 6-9 separate experiments were necessary to detaect differences of 25%-30%. In order to be sure that a 25%-30% difference is not present, 15-21 experiments were required. Using a Dec-20 computer, 1000 samples of sample size 3, 4, or 10 were drawn from the 66 experiments; it was found that with 3 experiments and a true value of 23%, the actually observed value was below 10%, 17% of the time, and was over 40% in 10% of the samplings. In a smaller number of experiments similar results were obtained analyzing 3HTdR suicide of pluripotent stem cells and CFU- C. These data could provide a base from which to judge the validity of studies utilizing the CFU-C technique. 相似文献
38.
Maria E. Marketou MD PhD Fragiskos I. Parthenakis MD PhD Athanasia Kalyva PhD Charalampos Pontikoglou MD PhD Spyros Maragkoudakis MD PhD Joanna E. Kontaraki PhD Evangelos A. Zacharis MD PhD Gregory Chlouverakis PhD Alexandros Patrianakos MD PhD Helen A. Papadaki MD PhD Panos E. Vardas MD PhD 《Journal of clinical hypertension (Greenwich, Conn.)》2014,16(12):883-888
Stem cells have great clinical significance in many cardiovascular diseases. However, there are limited data regarding the involvement of mesenchymal stem cells (MSCs) in the pathophysiology of arterial hypertension. The aim of this study was to investigate the circulation of MSCs in patients with essential hypertension. The authors included 24 patients with untreated essential hypertension and 19 healthy individuals. Using flow cytometry, MSCs in peripheral blood, as a population of CD45−/CD34−/CD90+ cells and also as a population of CD45−/CD34−/CD105+ cells, were measured. The resulting counts were translated into the percentage of MSCs in the total cells. Hypertensive patients were shown to have increased circulating CD45−/CD34−/CD90+ compared with controls (0.0069%±0.012% compared with 0.00085%±0.0015%, respectively; P=.039). No significant difference in circulating CD45−/CD34−/CD105+ cells was found between hypertensive patients'' and normotensive patients'' peripheral blood (0.018%±0.013% compared with 0.015%±0.014%, respectively; P=.53). Notably, CD45−/CD34−/CD90+ circulating cells were positively correlated with left ventricular mass index (LVMI) (r=0.516, P<.001). Patients with essential hypertension have increased circulating MSCs compared with normotensive patients, and the number of MSCs is correlated with LVMI. These findings contribute to the understanding of the pathophysiology of hypertension and might suggest a future therapeutic target.In recent years there has been growing interest in the role of adult stem cells in the pathophysiology of cardiovascular diseases. Although it used to be believed that mammalian cardiomyocytes cease replication soon after birth and that the subsequent growth of the heart was attributable only to cardiomyocyte hypertrophy, newer studies have demonstrated a small degree of cardiogenesis and cardiomyocyte turnover that occurs throughout life.1, 2 These findings led to further research into the contribution of stem cells to the pathophysiology of cardiovascular disorders that has raised the hope of developing new therapeutic approaches. Stem cells have the potential for self‐renewal and differentiation and are the origin cells of various mature cells.Mesenchymal stem cells (MSCs) are also known to have a highly plastic differentiation potential that includes not only adipogenesis, osteogenesis, and chondrogenesis, but also endothelial, cardiovascular,3 and neovascular differentiation.4, 5, 6 Although present in only very small numbers in peripheral blood, in recent years stem and progenitor cells have been implicated in ventricular remodeling and are thought to be of great clinical significance in the pathophysiology of heart failure and atheromatosis. Previous studies have indicated that MSCs derived from peripheral blood, apart from their multilineage potential, can also be used for cellular and gene therapies.7 Human MSCs isolated from adult bone marrow provide a model for the development of stem cell therapeutics and could find application in the cardiovascular system—although this is still under investigation.8 Under normal conditions, endogenous cardiac progenitor cells are responsible for homeostasis in the heart.9 However, it appears that under conditions of stress, this may change, with stem cells from extra‐cardiac sources also playing a role. An interesting experimental study has shown that an increase in preload results in the mobilization of progenitor cells from the bone marrow for use in neovascularization, which plays an important role in cardiac hypertrophy.10 There are indications that the recruitment of bone marrow–derived cells is involved in cardiac myocyte hypertrophy and maintenance of function in response to pressure overload.11 A recent study from our department has shown increased expression of myocardin and GATA4 genes in the peripheral blood mononuclear cell fraction of hypertensive patients, implying the presence of mesenchymal progenitor cells in the peripheral blood that could possibly be intended to differentiate into cells of the cardiac series.12 Interestingly, in the patients in that study, myocardin and GATA4 expression was associated with both blood pressure (BP) levels and left ventricular hypertrophy (LVH).To date, most published reports concerning the cardiovascular applications of stem cells have focused on their role in myocardial infarction and in heart failure. Very little work has been done on arterial hypertension, and most has concerned endothelial progenitor cells. The role and behavior of MSCs in patients with essential hypertension is unknown. In a recent animal study, it was shown that the degree to which angiotensin II increased neointima formation was statistically correlated with the increased incorporation of fluorescent bone marrow–derived smooth muscle cells, and that this was inhibited by angiotensin‐1 receptor antagonism.13 Based on the hypothesis that MSCs participate in pathophysiological processes that contribute to hypertension, and on the assumption that the behavior of MSCs is altered in hypertensive patients, we carried out the first flow cytometric analysis of CD45−/CD34−/CD90+ and CD45−/CD34−/CD105+ in the peripheral blood of those patients compared with healthy individuals. 相似文献
39.
该文旨在对小唾液腺癌的治疗进行回顾。小唾液腺癌可发生在头颈部很多位置,通常表现为黏膜下肿块。影像学检查是对肿瘤发病部位及病变范围内解剖结构的关系进行评估的基础。切取活检或穿吸活检可以决定肿瘤的病理类型和分级。随着分子生物学技术的不断进步,小唾液腺癌的诊断 相似文献
40.
PDE5 inhibition against acute renal ischemia reperfusion injury in rats: does vardenafil offer protection? 总被引:1,自引:0,他引:1
Iason Kyriazis George C. Kagadis Panagiotis Kallidonis Ioannis Georgiopoulos Antonia Marazioti Aikaterini Geronasiou Despοina Liourdi George Loudos Vasilios Schinas Dimitris Apostolopoulos Helen Papadaki Christodoulos Flordellis George C. Nikiforidis Andreas Papapetropoulos Evangelos Ν. Liatsikos 《World journal of urology》2013,31(3):597-602